.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
US Army
Fuji
Citi
Mallinckrodt
Baxter
Colorcon
Cerilliant
Chinese Patent Office
Novartis

Generated: June 29, 2017

DrugPatentWatch Database Preview

Testosterone - Generic Drug Details

« Back to Dashboard

What are the generic sources for testosterone and what is the scope of testosterone freedom to operate?

Testosterone
is the generic ingredient in eighteen branded drugs marketed by Eli Lilly And Co, Abbvie, Auxilium Pharms Inc, Watson Labs, Actavis Labs Ut Inc, Auxilium Pharms Llc, Par Pharm, Perrigo Israel, Alza, Endo Pharms, Ani Pharms Inc, Aytu Bioscience Inc, Allergan Sales Llc, Upsher-smith Labs, Sandoz Inc, Sun Pharm Inds Ltd, Paddock Llc, Watson Pharms Inc, Pharmacia And Upjohn, Hikma Farmaceutica, Mylan Institutional, West-ward Pharms Int, Bel Mar, Lilly, Elkins Sinn, and Endo Pharms Inc, and is included in forty-eight NDAs. There are forty-six patents protecting this compound and six Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Testosterone has three hundred and eighty-eight patent family members in forty-seven countries.

There are sixty-one drug master file entries for testosterone. Seventeen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: testosterone

Tradenames:18
Patents:46
Applicants:26
NDAs:48
Drug Master File Entries: see list61
Suppliers / Packagers: see list17
Bulk Api Vendors: see list52
Clinical Trials: see list728
Patent Applications: see list9,898
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:testosterone at DailyMed

Pharmacology for Ingredient: testosterone

Ingredient-typeAndrostanes
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists

Tentative approvals for TESTOSTERONE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe30MG/1.5MLSOLUTION;TOPICAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Israel
TESTOSTERONE
testosterone
SOLUTION, METERED;TRANSDERMAL204255-001Feb 28, 2017ATRXNoNo► Subscribe► Subscribe
Sun Pharm Inds Ltd
TESTOSTERONE CYPIONATE
testosterone cypionate
INJECTABLE;INJECTION201720-002Jun 3, 2013AORXNoNo► Subscribe► Subscribe
Mylan Institutional
TESTOSTERONE ENANTHATE
testosterone enanthate
INJECTABLE;INJECTION040647-001Oct 5, 2009AORXNoNo► Subscribe► Subscribe
Watson Labs
TESTOSTERONE ENANTHATE
testosterone enanthate
INJECTABLE;INJECTION083667-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Hikma Farmaceutica
TESTOSTERONE CYPIONATE
testosterone cypionate
INJECTABLE;INJECTION091244-001May 1, 2012AORXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: testosterone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alza
TESTODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL019762-002Oct 12, 19934,725,439► Subscribe
Alza
TESTODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL019762-001Oct 12, 19934,867,982► Subscribe
Alza
TESTODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL019762-002Oct 12, 19934,867,982► Subscribe
Alza
TESTODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL019762-002Oct 12, 19934,704,282► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 20108,071,075► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: testosterone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,153,845Bioadhesive progressive hydration tablets► Subscribe
2,014,073,618► Subscribe
7,157,097Penetration enhancing and irritation reducing systems► Subscribe
6,916,486 Transdermal delivery of analgesics► Subscribe
7,438,203Dermal penetration enhancers and drug delivery systems involving same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: testosterone

Country Document Number Estimated Expiration
South Korea100861603► Subscribe
Eurasian Patent Organization019214► Subscribe
Argentina047722► Subscribe
Portugal1011632► Subscribe
Australia8699501► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TESTOSTERONE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012 00010Denmark► Subscribe
2012 00012Denmark► Subscribe
973Luxembourg► Subscribe91973, EXPIRES: 20220219
00521Netherlands► SubscribePRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
972Luxembourg► Subscribe91972, EXPIRES: 20220219
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Merck
Dow
US Army
Deloitte
McKesson
Teva
Argus Health
Cerilliant
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot